Navigation Links
Fish Oil and Red Yeast Rice Studied for Lowering Blood Cholesterol
Date:7/8/2008

ROCHESTER, Minn., July 8 /PRNewswire-USNewswire/ -- A great deal of scientific evidence shows that cholesterol-reducing medications known as statins can help prevent coronary artery disease. Although the safety of these medications has been well documented, as many as 40 percent of patients who receive a prescription for statins take the drug for less than one year. Doctors believe that several factors -- including cost, adverse effects, poor understanding of statin benefits and patients' reluctance to take prescription medications long term -- may explain why some patients stop taking these medicines. In the July issue of Mayo Clinic Proceedings, a group of researchers from Pennsylvania examine whether an alternative approach to treating high blood cholesterol may provide an effective treatment option for patients who are unable or unwilling to take statins.

Study design

Researchers followed 74 patients with high blood cholesterol who met standard criteria for using statin therapy. Patients were randomly assigned to either the alternative treatment group or the statin group and followed for three months.

The alternative treatment group participants received daily fish oil and red yeast rice supplements, and they were enrolled in a 12-week multidisciplinary lifestyle program that involved weekly 3.5-hour educational meetings led by a cardiologist, dietitian, exercise physiologist and several alternative or relaxation practitioners. Red yeast rice is the product of yeast grown on rice. A dietary staple in some Asian countries, it contains several compounds known to inhibit cholesterol production.

The statin group participants received 40 milligrams (mg) of Zocor (simvastatin) daily, as well as printed materials about diet and exercise recommendations. At the end of the three-month period, participants from both groups underwent blood cholesterol testing to determine the percentage change in LDL cholesterol.

Results

The researchers noted that there was a reduction in LDL cholesterol levels in both groups. The alternative treatment group experienced a 42.4 percent reduction, and the statin group experienced a 39.6 percent reduction. Members of the alternative therapy group also had a substantial reduction in triglycerides, another form of fat found in the blood, and lost more weight.

"Our study was designed to test a comprehensive and holistic approach to lipid lowering," notes the study's lead author, David Becker, M.D., a Chestnut Hill Hospital and University of Pennsylvania Health System cardiologist. "These results are intriguing and show a potential benefit of an alternative, or naturopathic, approach to a common medical condition."

Dr. Becker acknowledges that a larger, multicenter trial with longer follow-up is necessary to determine long-term compliance with the alternative regimen, because previous studies involving diet and exercise have found a high rate of patients unable or unwilling to follow lifestyle recommendations.

"The excellent adherence in the alternative group was undoubtedly related to the intensive follow-up, education and support provided for this group," says Dr. Becker.

Other authors of this article include: Ram Gordon, M.D., Patti Morris, and Jacqueline Yorko, M.Ed., from Chestnut Hill Hospital and the University of Pennsylvania Health System; Y. Jerold Gordon, M.D., from the University of Pittsburgh School of Medicine; Mingyao Li, Ph.D., from the University of Pennsylvania School of Medicine; and Nayyar Iqbal, M.D., from the Philadelphia VA Medical Center/University of Pennsylvania.

A peer-review journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 80 years and has a circulation of 130,000 nationally and internationally. Articles are available online at http://www.mayoclinicproceedings.com.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
2. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
5. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
6. Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
10. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
11. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and Scannerside ... solution. Scannerside DoseCheck is a third-party Vendor neutral CT ... scanners and allows compliance with current MITA standards. ... XR 29 DoseCheck solution is specifically designed to provide ... of potential radiation doses over a predefined threshold. Scannerside ...
(Date:9/5/2017)... Sept. 5, 2017  Getinge, a leading global ... vibrant charitable donation program -- "Color for the ... heart defect research by The Children,s Heart Foundation. ... general public are encouraged to download a coloring ... completed artwork to the gallery on the website. ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... of providing a voice for people who have kidney disease. The theme “Describe ... to share their stories. Entrants needed to meet only one qualification— to ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... roster of exhibitors at the East-coast edition of MarTech: The Marketing Tech Conference ... will bring together more than 40 speakers — representing such thought-leading companies ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gather for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New ... It is also when Athletic Trainers are acknowledged by their peers with accolades ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare and Medicaid Services ... will transition to using only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated ... 60-minute complimentary webinars on October 17, 2017 at 2 P.M. EST and ...
(Date:9/20/2017)... ... ... Trials I Face to Receive God’s Grace”: a mesmerizing take on one man’s ... one’s life through God. “The Trials I Face to Receive God’s Grace” is the ... a love for writing. Green feels that expressing his feelings through prayer will present ...
Breaking Medicine News(10 mins):